viewVentriPoint Diagnostics Ltd.

Ventripoint Diagnostics arranges C$1M private placement of debenture units

Proceeds will be used for sales and marketing, development and general working capital

Medical person holding heart symbol
The company uses artificial intelligence to create applications monitoring heart disease

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCMKTS:VPTDF) said Wednesday that it plans to complete a non-brokered private placement of as much as C$1 million debenture units.

The proceeds will be used for sales and marketing, development and general working capital, the Toronto-based, heart-focused medical device company said in a press release.

READ: Ventripoint Diagnostics shares pump after positive findings from sarcoidosis study in Netherlands using VMS

Each unit of the offering will include a principal amount of C$1,000 in convertible, unsecured debentures maturing in three years, as well as 6,000 common share purchase warrants, with each warrant exercisable for one common share at C$0.175 per share for 18 months.

The debentures may be converted at any time following the date of issuance at C$0.155 per common share.

Shares of Ventripoint slipped C$0.01 to C$0.18 in Tuesday’s Canadian trading. They were down US$0.01 to US$0.13 on the OTC Markets.

Depending on market conditions, Ventripoint said it has the right to increase the maximum gross proceeds under the offering, subject to the approval of the TSX Venture Exchange.

The debentures will have an annual interest rate of 6.5%, and the company may pay a finder's fee of up to 7% of the gross proceeds.

Ventripoint uses an artificial intelligence (AI) method known as knowledge-based reconstruction to create applications monitoring heart disease.

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

Quick facts: VentriPoint Diagnostics Ltd.

Price: 0.11 CAD

Market: TSX-V
Market Cap: $7.67 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VentriPoint Diagnostics Ltd. named herein, including the promotion by the Company of VentriPoint Diagnostics Ltd. in any Content on the Site,...


Ventripoint Diagnostics new Director sees strong path forward updated VMS system

Ventripoint Diagnostics (CVE: VPT-OTC: VPTDF) New Director Hugh MacNaught joined Steve Darling from Proactive to discuss his new role on the board of the company. He also shares his background and what he brings to the company. MacNaught also shared details about the news VMS technology and...

1 week, 5 days ago

2 min read